Common Contracts

Contract

Collaboration Agreement • May 5th, 2020 • New York

• Contract Type
  Collaboration Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

EX-10.44 5 amgn-ex1044collaborationag.htm COLLABORATION AGREEMENT Exhibit 10.44 Execution Version Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND NOVARTIS PHARMA AG DATED APRIL 21, 2017 Amgen Ref. No. 2017747574 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. Table of Contents PAGE

COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND NOVARTIS PHARMA AG DATED APRIL 21, 2017

Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York

• Contract Type
  Collaboration Agreement
• Filed
  July 26th, 2017
• Company
  Amgen Inc
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This Collaboration Agreement (this “Agreement”), effective as of April 21, 2017 (the “Effective Date”), is by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Novartis Pharma AG, a Swiss company having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Amgen and Novartis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”